Sicentist Reveals Cost Effective to Test for All Lung Cancer Mutations at Once

[yungcrux]

BOOK INTERNATIONAL FLIGHTS TICKETS LOCAL FLIGHTS HOTELS BOOKINGS WORLDWIDE AND MORE AT CHEAPEST RATE EVER! CLICK HERE TO BOOK YOUR FLIGHT AND RECEIVE YOUR FLIGHT TICKET INSTANTLY

Loading...

Testing advanced lung cancer patients for all of the possible genetic mutations that could be driving their cancer at once is more cost effective than testing for one or a limited number of genes at a time, U.S. researchers reported Wednesday.

There are eight targeted therapies doctors can use to treat nonsmall-cell lung cancer (NSCLC) patients based on genetic defects, and more treatments are in clinical trials or awaiting approval.

Companies such as Foundation Medicine Inc. and Thermo Fisher Scientific Inc. offer genetic profiling tests using so-called next-generation sequencing that can identify hundreds of potential cancer-causing gene mutations from a small tissue sample at once. These tests are used to match patients to specific therapies targeting those genes or to clinical trials testing new drugs.

Insurance companies have been slow to pay for sequencing for all possible mutations at once, arguing such comprehensive testing amounts to funding research, not medical care. They often require doctors to test for individual genes sequentially or use a limited panel that looks for suspect genes associated with approved treatments.

“Our results showed there were substantial cost savings compared with all the other strategies,” Dr. Nathan Pennell of the Cleveland Clinic’s lung cancer program said in a telephone briefing Wednesday.